UroAlert - GU Oncology Weekly

December 11, 2024

Videos

Peer-to-Peer Clinical Conversations

Expanded Access Program Provides Early Cretostimogene Therapy for Bladder Cancer - Sarah Psutka

Sarah Psutka

Sarah Psutka examines the expanded access program (EAP) for cretostimogene in BCG-unresponsive bladder cancer.

Integrating Genomic Testing with MRI Enhances Stratification of Surveillance Patients - Eric Kim & Mark Sultan

Eric Kim

Mark Sultan and Eric Kim discuss research on predicting prostate cancer progression during active surveillance using Decipher® genomic classifier scores and MRI characteristics.

Beyond the Abstracts

Metastasis Development in Non-Muscle-Invasive Bladder Cancer - Beyond the Abstract

Impact of TP53 Loss-of-Function Alterations on the Response to PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients - Beyond the Abstract

Conference Coverage

SUO 2024: Biomarkers and Clinical Predictors in RCC

SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting

SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Focal Ablation

SUO 2024: Preventing and Managing Long Term Complications of Radical Cystectomy

SUO 2024: Efficacy and Safety of Padeliporfin VTP for Treatment of Low-Grade UTUC: ENLIGHTED Phase 3 study

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy.

Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function.

Safety and efficacy of the MP1000 surgical system in robot-assisted radical cystectomy: A prospective study.

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

Co-inhibition of PGF and VEGFA enhances the effectiveness of immunotherapy in bladder cancer.

High-Risk Non-Muscle Invasive Bladder Cancer: outcomes of patients who cannot benefit from Standard of Care.

Virtual simulator for cystoscopy containing motion blur and bladder debris to aid the development of clinical tools.

IMFINZI® (durvalumab) Granted Priority Review in the US for Patients with Muscle-invasive Bladder Cancer

Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.

The impact of positive surgical margins after cystectomy on oncological outcomes: a nationwide study.

Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, and uromonitor® in comparison to cytol

Long-term quality of life in patients with bladder cancer following radical cystectomy.

Metastasis Development in Non-Muscle-Invasive Bladder Cancer - Beyond the Abstract

Tumor Location at Trans-Urethral Resection Is Predictive of Ipsilateral Pelvic Lymph-Nodal Metastases in Patients Undergoing Radical Cystectomy for Bladder Cancer - Beyond the Abstract

Penile & Urethral Cancers

Factor associated with postoperative complications of inguinal lymph node dissection for penile cancer Test.

Renal Cancer

Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma.

Computed Tomography Measures of Perinephric Adipose Tissue and C-Reactive Protein-to-Albumin Ratio are Associated with Common Prognostic Models for Nonmetastatic Clear Cell Renal Cell Carcinoma Patients.

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.

Diagnostic and prognostic potential of FBXO8 expression in kidney renal clear cell carcinoma and its regulation of renal adenocarcinoma cells.

Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma.

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.

Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment.

Retrograde aortic dissection encountered amidst nephrectomy for renal cell carcinoma with IVC thrombus - a case report.

Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?

Normothermic cardiopulmonary bypass and beating heart surgery for renal cell cancer with tumor thrombus extension into inferior vena cava and right atrium: a less invasive strategy.

Predictive nomogram for ischemic stroke risk in clear cell renal cell carcinoma patients.

Prostate Cancer

Novel bioabsorbable, low-dose rate brachytherapy device (CivaSheet®) with radical prostatectomy and adjuvant external beam radiation for the management of prostate cancer.

Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer.

Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer.

A Prostate Imaging-Reporting and Data System version 2.1-based predictive model for clinically significant prostate cancer diagnosis.

Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer.

ERG and PTEN Role on Active Surveillance for Low-Risk Prostate Cancer in the Multiparametric MRI Era.

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.

Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.

Hospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery.

Spatial Transcriptomic Profiling to Characterize the Nature of Peripheral- Versus Transition-zone Prostate Cancer.

The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy.

Survival Outcomes and Recurrence Patterns Following Focal High-intensity Focused Ultrasound Treatment for Localized Prostate Cancer: Insights on Patient Selection and Lessons Learned.

Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison.

Ultra-high gradient performance 3-Tesla MRI for super-fast and high-quality prostate imaging: initial experience.

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer.

Artificial intelligence for detection of prostate cancer in biopsies during active surveillance.

Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men.

Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer.

Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers.

Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer.

Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data.

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy.

Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study.

Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.

Meeting Aerobic Physical Activity Guidelines and Associations With Physical Fitness in Men With Metastatic Prostate Cancer: Baseline Results of the Multicentre INTERVAL-GAP4 Trial.

Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A secondary analysis of a randomized clinical trial.

Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.

Post-prostatectomy Magnetic Resonance-guided Radiotherapy on a 1.5 Tesla Magnetic Resonance Integrated Linear Accelerator: Feasibility, Toxicity, and Preliminary Clinical Outcomes.

Immunome profiling in prostate cancer: a guide for clinicians.

Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy.

Transperineal 3D fusion imaging-guided targeted microwaves ablation for low to intermediate-risk prostate cancer: results of a phase I-II study.

Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology.

In-field prostate cancer recurrence following radical prostatectomy and salvage radiation.

Lutetium-177-prostate-specific membrane antigen therapy for prostate cancer: current status and future prospects.

Irish Prostate Cancer Outcomes Research (IPCOR) registry: cohort profile.

Docetaxel Versus Androgen-Receptor Signaling Inhibitors as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

Coagulation Factor X Promotes Resistance to Androgen-Deprivation Therapy in Prostate Cancer - Beyond the Abstract

Upper Tract Tumors

Minimizing overtreatment and maximizing oncologic outcomes in upper tract urothelial carcinoma.

Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma - Beyond the Abstract

Testicular Cancer

Evaluation of CacyBP/SIP expression and its relationship with ERK1/2 and p38 kinase in testicular seminoma.

Laparoscopic Retroperitoneal Lymph Node Dissection After Chemotherapy for Nonseminomatous Testicular Germ-Cell Tumor at a Single Center.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC